Guerbet

Guerbet FCF per Share

The Free Cash Flow per Share of Guerbet (GBT.PA) as of Nov 22, 2026 is 2.49 EUR. In the previous year, Free Cash Flow per Share was 3.90 EUR — a change of -36.28% (lower).

FCF per Share

2.49EUR

YoY

-36.28%

Last updated:

Free Cash Flow per Share of Guerbet is 2025 2.49 EUR. Free Cash Flow per Share of Guerbet was 2024 3.90 EUR. It decreases by -36.28% lower compared to the previous year.

The Guerbet FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
3.49 EUR
Jan 1, 2019
5.68 EUR
Jan 1, 2020
4.77 EUR
Jan 1, 2021
5.30 EUR
Jan 1, 2022
-1.59 EUR
Jan 1, 2023
-2.19 EUR
Jan 1, 2024
3.90 EUR
Jan 1, 2025
2.49 EUR
The Guerbet FCF per Share history
YEARFCF per ShareYoY
2.49EUR-36.28%
3.90EUR-277.89%
-2.19EUR+37.84%
-1.59EUR-130.01%
5.30EUR+11.18%
4.77EUR-15.99%
5.68EUR+62.70%
3.49EUR+48.74%
2.35EUR+483.21%
0.40EUR-88.83%
3.60EUR+18.85%
3.03EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guerbet Stock analysis

What does Guerbet do? Guerbet SA is a global corporation specializing in medical imaging solutions. The company was founded in France in 1926 and is named after Marcel Guerbet, a chemist who developed the first iodine-based contrast agent for x-ray examination of blood vessels. Guerbet specializes in four main business areas: imaging solutions, X-ray contrast agents, interventional products, and diagnostic solutions. The portfolio includes contrast agents used in X-ray examinations as well as devices used in various medical imaging procedures such as CT or MRI. Guerbet's imaging solutions help doctors make accurate diagnoses and plan treatments. The X-ray contrast agent division is the heart of the company, and Guerbet is the second-largest provider of iodine-based X-ray contrast agents worldwide. Guerbet's interventional products are specifically designed for the minimally invasive treatment of conditions such as liver tumors. These include needles, catheters, and embolization materials. Guerbet's diagnostic solutions include various software solutions specialized in medical imaging and radiology. Guerbet is committed to constantly developing and improving its products and services. For example, the company has developed a new generation of contrast agents that are less toxic and gentler on the body. Guerbet is also working on the development of new minimally invasive techniques and materials in the field of interventions. Another important aspect of Guerbet's business philosophy is sustainability. The company actively promotes environmental protection and strives to make its products and services as environmentally friendly as possible. This includes the development of contrast agents that are biodegradable. Overall, Guerbet is a company specializing in medical imaging solutions and is characterized by continuous innovation and sustainability. The various divisions of the company work closely together to provide the best possible treatment for doctors and patients. Guerbet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guerbet stock

Free Cash Flow per Share of Guerbet is 2.49 EUR in 2025.

Free Cash Flow per Share of Guerbet changed from 3.90 EUR to 2.49 EUR, representing a -36.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Guerbet since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Guerbet

All Key Metrics — Guerbet